Novel Agents With User Fee Goals In The Upcoming Year
This article was originally published in Pharmaceutical Approvals Monthly
Selected novel drug and biologic applications with FDA action goals in the next 12 months.
You may also be interested in...
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Spironolactone TOPCAT Regional Analysis Falls Short At US FDA AdComm, But Hospitalizations Drive Vote
A new indication for the generic diuretic in heart failure with preserved ejection fraction gets an 8-4 vote, with one abstention, despite troubles an analysis that tries to revive the TOPCAT trial with an analysis excluding Eastern European sites – or about half the participants.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.